MedTrace Logo

Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC

NCT02047201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-03-02

No results posted yet for this study

Summary

To evaluate the safety and efficacy of cisplatin plus intensity-modulated radiotherapy (IMRT) based on FDG-PET/CT after induction chemotherapy (IC) for locally advanced head and neck squamous cell carcinoma.

Conditions

Interventions

RADIATION

IMRT

IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).

RADIATION

PET/CT

Assessing tumor response using FDG-PET/CT.

DRUG

Docetaxel

75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.

DRUG

Fluorouracil

750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.

DRUG

Cisplatin

75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.

Sponsors & Collaborators

  • Lithuanian University of Health Sciences

    lead OTHER

Principal Investigators

  • Ilona Kulakiene, Prof. · Lithuanian University of Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Lithuania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047201 on ClinicalTrials.gov